Changing the treatment paradigm for somatostatin receptor-positive tumors
Because more patients need more options
Expanding targeted treatment beyond SSTR2
Grafton Therapeutics has created new high-affinity dual SSTR2-SSTR5 agents.
Expanding
Treatment Options
Expanding Treatment Options
Our approach expands patient populations beyond those eligible for SSTR2-only radioligand and peptide medical treatments.
Enhancing the
Anti-Tumoral Effects
Enhancing the Anti-Tumoral Effects
Increasing anti-tumoral activity through dual SSTR2 and SSTR5 agonism both in radioligand and in chronic medical therapy
Optimizing the
Safety Profile
Optimizing the Safety Profile
Our novel radioligand and linker promise improved pharmacokinetics and biodistribution for alpha and beta therapy
Large addressable market
of NET tumors are
SSTR5 positive
SSTR5 positive
0
%
Target SSTR2 and SSTR5 simultaneously to increase the range of treatable tumors.
Gut and pancreatic NET Meningioma Colorectal Cancer Cushing's Disease (pituitary) Acromegaly (pituitary) Prostate Cancer (neuroendocrine) Non-Small Cell Lung Cancer Pulmonary NET Breast (neuroendocrine) Central Neurocytomas Melanoma (uveal)
Gut and pancreatic NET Meningioma Colorectal Cancer Cushing's Disease (pituitary) Acromegaly (pituitary) Prostate Cancer (neuroendocrine) Non-Small Cell Lung Cancer Pulmonary NET Breast (neuroendocrine) Central Neurocytomas Melanoma (uveal)
Gut and pancreatic NET Meningioma Colorectal Cancer Cushing's Disease (pituitary) Acromegaly (pituitary) Prostate Cancer (neuroendocrine) Non-Small Cell Lung Cancer Pulmonary NET Breast (neuroendocrine) Central Neurocytomas Melanoma (uveal)
Improving the standard of care in RLT
Tumors and metastases have complex SSTR expression and could vary over time.
Our novel approach expands current therapies possibilities.
Tumors and metastases have complex SSTR expression and could vary over time.
Our novel approach expands current therapies possibilities.
Current therapies
-
SSTR2 only
-
SSTR5 only
-
Mixed (SSTR2 + SSTR5)
Grafton approach
-
SSTR2 only
-
SSTR5 only
-
Mixed (SSTR2 + SSTR5)
Our milestones so far...
2021
- Grafton Therapeutics designs new high-affinity SSTR2/SSTR5 agents
- Lead compounds have sub-nanomolar affinities at SSTR2 and SSTR5
2022
- Worldwide IP filed
- Development of high-affinity SSTR2/SSTR5 radiopharmaceuticals with novel linker elements
2023
- Potent inhibition of hormonal secretion and proliferation in NET and pituitary tumor models
2024
- Long-term mechanistic studies in 2D and 3D NET cultures completed
- Testing of novel alpha and beta radiolabeled conjugates
Meet our team
Alan Harris
MD PhD, Founder & CEO
Adrian F. Daly
MD PhD, Chief Scientific Officer
Elcin Zan
MD, Principal Medical Advisor
